A genomic "roadmap" to "better" drugs

Drug Metabolism Reviews

Volumn 40, Issue 2, 2008, Pages 225-239

  Liao, Guochun ^a   Zhang, Xun ^a   Clark, David J ^b,c   Peltz, Gary ^a  

^a Roche Palo Alto ^*  (United States)

^b STANFORD UNIVERSITY   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Computational Genetics; In silico pharmacogenetics; Pharmacogenetics

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CARMUSTINE; DIHYDROMOTUPORAMINE C; FLUOROURACIL; IRINOTECAN; METHOTREXATE; MORPHINE; TESTOSTERONE; TIOGUANINE; TOLBUTAMIDE; WARFARIN; DRUG;

DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSFORMATION; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; GENOME ANALYSIS; GENOMICS; GENOTOXICITY; HUMAN; LIVER TOXICITY; NONHUMAN; PATIENT CARE; PHARMACOGENOMICS; REVIEW; TECHNIQUE; TECHNOLOGY; BIOLOGY; BIOTRANSFORMATION; DRUG DESIGN; DRUG MONITORING; GENETIC SCREENING; GENETICS; GENOTYPE; METABOLISM; METHODOLOGY; PATIENT SELECTION; PHARMACOGENETICS; PHENOTYPE;

BIOTRANSFORMATION; COMPUTATIONAL BIOLOGY; DRUG DESIGN; DRUG MONITORING; GENETIC SCREENING; GENOMICS; GENOTYPE; HUMANS; PATIENT SELECTION; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHENOTYPE; VARIATION (GENETICS);

EID: 44649145927     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.1080/03602530801952815     Document Type: Review

References (52)

1. Baetz, K., McHardy, L., Gable, K., Tarling, T., RebÇrioux, D., Bryan, J., Andersen, R.J., Dunn, T., Hieter, P., and Roberge, M. (2004). Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action. Proc Natl Acad Sci USA 101:4525-4530.
2. Bild, A., Yao, G., Chang, J., Wang, Q., Potti, A., Chasse, D., Joshi, M., Harpole, D., Lancaster, J., Berchuck, A., et al. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353-357.
3. Brenner, C. (2004). Chemical genomics in yeast. Genome Biol. 5:240-244.
4. Carrasco, D.R., Tonon, G., Huang, Y., Zhang, Y., Sinha, R., Feng, B., Stewart, J.P., Zhan, F., Khatry, D., and Protopopova, M. (2006). High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9:313-325.
5. Cervino, A.C., Li, G., Edwards, S., Zhu, J., Laurie, C., Tokiwa, G., Lum, P.Y., Wang, S., Castellini, L.W., Lusis, A.J., et al. (2005). Integrating QTL and high-density SNP analyses in mice to identify Insig2 as a susceptibility gene for plasma cholesterol levels. Genomics 86:505-517.
6. Chanock, S. J., Manolio, T., Boehnke, M., Boerwinkle, E., Hunter, D. J., et al. (2007b). Replicating genotype-phenotype associations. Nature 447:655-660.
7. Clayton, T., Lindon, J., Cloarec, O., Antti, H., Charuel, C., Hanton, G., Provost, J., Le, N., Baker, D., Walley, R., et al. (2006). Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440:1073-1077.
8. Drummelsmith, J., Brochu, V., Girard, I., Messier, N., Ouellette, M. (2003). Proteome mapping of the protozoan parasite Leishmania and application to the study of drug targets and resistance mechanisms. Mol. Cell. Proteom. 2:146-155.
9. Drummelsmith, J., Girard, I., Trudel, N., Ouellette, M. (2004). Differential protein expression analysis of Leishmania major reveals novel roles for methionine adenosyltransferase and S-adenosylmethionine in methotrexate resistance. J. Biol. Chem. 279:33273-33280.
10. Easton, D.F., Pooley, K.A., Dunning, A.M., Pharoah, P.D.P., Thompson, D., Ballinger, D.G., Struewing, J.P., Morrison, J., Field, H., Luben, R., et al. (2007). Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:1087-1093.
11. Ewens, A., Luo, L., Berleth, E., Alderfer, J., Wollman, R., Hafeez, B., Kanter, P., Mihich, E., and Ehrke, M. (2006). Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Res. 66:5419-5426.
12. Fan, C., Oh, D.S., Wessels, L., Weigelt, B., Nuyten, D.S.A., Nobel, A.B., van't Veer, L.J., Perou, C.M. (2006). Concordance among gene-expression-based predictors for breast cancer. New Engl. J. Med. 355:560-569.
13. Feng, B., Mills, J., Mireles, R., Janiszewsiki, J., Troutman, M., Morais, S. (2007). In Vitro P-glyprotein assays to predict the clinical interactions of pglycoprotein with drugs in the central nervous system. Drug Metab. Dispos. In press.
14. Gagne, J.F., Montminy, V.B.P., Gaucher, G., Guillemette, C. (2002). Common Human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol. Pharmacol. 62:608-617.
15. Galloway, S.M. (2000). Cytotoxicity and chromosome aberrations in vitro: experience in industry and the case for an upper limit on toxicity in the aberration assay. Environ. Mol. Mutagen. 35:191-201.
16. Ganter, B., Tugendreich, S., Pearson, C.I., Ayanoglu, E., Baumhueter, S., Bostian, K.A., Brady, L., Browne, L.J., Calvin, J.T., Day, G.J. (2005). Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J. Biotechnol. 119:219-244.
17. Guo, Y., Shafer, S., Weller, P., Usuka, J., Peltz, G. (2005). Pharmacogenomics and drug development. Pharmacogenomics 6: 857-864.
18. Guo, Y.Y., Liu, P., Zhang, X., Weller, P.M.M., Wang, J., Liao, G., Zhang, Z., Hu, J., Allard, J., Shafer, S., et al. (2007). In vitro and In silico Pharmacogenetic Analysis in Mice. Proc. Natl. Acad. Sci. 104:17735-17740.
19. Guo, Y.Y., Weller, P.F., Farrell, E., Cheung, P., Fitch, B., Clark, D., Wu, S.Y., Wang, J., Liao, G., Zhang, Z., et al. (2006). In Silico pharmacogenetics: Warfarin metabolism. Nature Biotechnol. 24:531-536.
20. Hakonarson, H., Grant, S.F.A., Bradfield, J.P., Marchand, L., Kim, C.E., Glessner, J.T., Grabs, R., Casalunovo, T., Taback, S.P., Frackelton, E.C., et al. (2007). A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature 448:591-594.
21. Hastwell, P.W., Chai, L.L., Roberts, K.J., Webster, T.W., Harvey, J.S., Rees, R.W., and Walmsley, R.M. (2006). High-specificity and high-sensitivity genotoxicity assessment in a human cell line: Validation of the GreenScreen HC GADD45a-GFP genotoxicity assay. Mutat. Res. 607:160-175.
22. Hu, T., Gibson, D.P., Carr, G.J., Torontali, S.M., Jay, P., Chaney, J.G., Aardema, M.J. (2004). Identification of a gene expression profile that discriminates indirect-acting genotoxins from direct-acting genotoxins. Mutation Research 549, 5-27.
23. Hudis, C.A. (2007). Trastuzumab - Mechanism of action and use in clinical practice. New Engl. J. Med. 357:39-51.
24. Isidori, A., Giannetta, E., Gianfrilli, D., Greco, E., Bonifacio, V., Aversa, A., Isidori, A., Fabbri, A., Lenzi, A. (2005). Effects of testosterone on sexual function in men: results of a meta-analysis. Clin. Endocrinol. 63:381-394.
25. Kirkland, D., Aardema, M., Henderson, L., Muller, L. (2005). Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I, Sensitivity, specificity and relative predictivity. Mutat. Res. 584:1-256.
26. Kleno, T.G., Kiehr, B., Baunsgaard, D., Sidelmann, U.G. (2004). Combination of 'omics' data to investigate the mechanisms of hydrazine-induced hepatotoxicity in rats and to identify potential biomarkers. Biomarkers 9:116-138.
27. Levitt, S.D., Dubner, S.J. (2005). Freakonomics. New York City, Harper Collins Publishers Inc.
28. Liang, D., Liao, G., Wang, J., Usuka, J., Guo, Y.Y., Peltz, G., Clark, J.D. (2006a). A genetic analysis of opioid-induced hyperalgesia in mice. Anesthesiology 104:1054-1062.
29. Liang, D.Y., Liao, G., Lighthall, G., Peltz, G., and Clark, J.D. (2006b). Genetic variants of the P-glycoprotein gene Abcb1b modulate opioid-induced hyperalgesia, tolerance and dependence. Pharmacogen. Genomics 16:825-835.
30. Liao, G., Wang, J., Guo, J., Allard, J., Chang, J., Nguyen, A., Shafer, S., Puech, A., McPherson, J.D., Foernzler, D., et al. (2004). In Silico genetics: Identification of a novel functional element regulating H2-Ea gene expression. Science 306:690-695.
31. Lu, P., Ragnan, A., Chan, S.Y., Appling, D.R., Hoffman, D.W., Marcotte, E.M. (2007). Global metabolic changes following loss of a feedback loop reveal dynamic steady states of the yeast metabolome. Metabolic Eng. 9:8-20.
32. Lum, P., Armour, C., Stepaniants, S., Cavet, G., Wolf, M., Butler, J., Hinshaw, J., Garnier, P., Prestwich, G., Leonardson, A., et al. (2004). Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 116: 121-137.
33. Moffatt, M.F., Kabesch, M., Liang, L., Dixon, A.L., Strachan, D., Heath, S., Depner, M., von Berg, A., Bufe, A., Rietschel, E., et al. (2007). Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 448:470-473.
34. Nagar, S., and Blanchard, R.L. (2006). Pharmacogenetics of Uridine Diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. Drug Metab. Rev. 38:393-409.
35. Newton, R.K., Aardema, M., Aubrecht, J. (2004). The utility of DNA microarrays for characterizing genotoxicity. Environ. Health Perspect. 112:420-422.
36. Noshiro, M., Lakso, M., Kawajiri, K., Negishi, M. (1988). Rip locus: regulation of female-specific isozyme I-P-45016 alpha of testosterone 16 alpha-hydroxylase in mouse liver, chromosome localization, and cloning of P-450 cDNA. Biochemistry 27:6434-6443.
37. Noshiro, M., and Negishi, M. (1988). Genetic regulation of estrogen-dependent repression of female-specific testosterone 16 alpha-hydroxylase I-P-45016 alpha in male mouse liver: murine Ripr locus. Biochemistry 27:6444-6448.
38. Parsons, A.B., Lopez, A., Givoni, I.E., Williams, D.E., Gray, C.A., Porter, J., Chua, G., Sopko, R., Brost, R.L., Ho, C.H. (2006). Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 126:611-625.
39. Pickering, L.A., Branca, M.A. (2006). Pharmaceutical industry dynamics has genomics failed to deliver? In D (Boston, MA, Decision Resources, Inc.), pp. 1-29.
40. Potti, A., Mukherjee, S., Petersen, R., Dressman, H.K., Bild, A., Koontz, J., Kratzke, R., Watson, M.A., Kelley, M., Ginsburg, G.S., et al. (2006). A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. New Engl. J. Med. 355:570-580.
41. Solit, D., Garraway, L., Pratilas, C., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J., She, Y., Osman, I., et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358-362.
42. Steiner, G., Suter, L., Boess, F., Gasser, R., de, V., Albertini, S., Ruepp, S. (2004). Discriminating different classes of toxicants by transcript profiling. Environ. Health Perspect. 112:1236-1248.
43. van, D., van, A., van, B., Herwijnen, M.H., Staal, Y., Kleinjans, J.C.S. (2004). Discrimination of genotoxic from non-genotoxic carcinogens by gene expression profiling. Carcinogenesis 25:1265-1276.
44. von der, H.W., Kalweit, S., Engelhardt, G., McKiernan, S., Kasper, P., Slacik, E.R., Miltenburger, H.G., Honarvar, N., Fahrig, R., Gîrlitz, B., et al. (2000). In vitro micronucleus assay with Chinese hamster V79 cells - results of a collaborative study with in situ exposure to 26 chemical substances. Mutat. Res. 468:137-163.
45. Walmsley, R.M. (2005). Genotoxicity screening: the slow march to the future. Expert Opin. Drug Metab. Toxicol. 1:261-268.
46. Wang, J., Liao, G., Chang, J., Nguyen, A., Guo, J., Chou, S., Hu, S., Bach, C., Allard, J., Shafer, S., et al. (2005a). Haplotypic structure of the mouse genome. In Computational Genetics and Genomics: New Tools for Understanding Disease (Totowa, New Jersey, Humana Press Inc.), pp. 71-83.
47. Wang, J., Liao, G., Usuka, J., Peltz, G. (2005b). Computational Genetics: From Mouse to Man? Trends Genetics 21:526-532.
48. Wang, J., Peltz, G. (2005). Haplotype-based computational genetic analysis in mice. In Computational Genetics and Genomics: New Tools for Understanding Disease (Totowa, New Jersey, Humana Press Inc.), pp. 51-70.
49. The Wellcome Trust Case Control Consortium (2007a). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661-678.
50. Yamazaki, M., Neway, W.E., Ohe, T., Chen, I.W., Rowe, J.F., Hochman, J.H., Chiba, M., Lin, J.H. (2001). In vitro substrate identification studies for p-glycoprotein-mediated transport: Species difference and predictability of in vivo results. J. Pharmacol. Exper. Therapeut. 296:723-735.
51. Yu, J., Pressoir, G., Briggs, W.H., Vroh Bi, I., Yamasaki, M., Doebley, J.F., McMullen, M.D., Gaut, B.S., Nielsen, D.M., Holland, J.B., et al. (2006). A unified mixed-model method for association mapping that accounts for multiple levels of relatedness. Nat. Genet. 38:203-208.
52. Zheng, M., Lu, P., Pease, J., Liao, G., Peltz, G. (2007). An automated method for analysis of 2-dimensional 1H 13C NMR Spectra. Bioinformatics 21:2926-2933.